Treatment with Candesartan Combined with Angiotensin-Converting Enzyme Inhibitor for Immunosuppressive Treatment-Resistant Nephrotic Syndrome after Allogeneic Stem Cell Transplantation
| Autor: | Takefumi Ishii, Masahiro Sako, Yuko Osugi, Misako Ikemiya, Hiroshi Yamada, Gaku Hosoi, Haruyoshi Noma |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Male
medicine.medical_specialty Nephrotic Syndrome Time Factors Adolescent Drug Resistance Urology Tetrazoles Angiotensin-Converting Enzyme Inhibitors urologic and male genital diseases Membranous nephropathy Internal medicine Humans Transplantation Homologous Medicine cardiovascular diseases Enalapril Antihypertensive Agents Proteinuria business.industry Biphenyl Compounds Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Tacrolimus Transplantation Candesartan surgical procedures operative Endocrinology Trough level Benzimidazoles medicine.symptom business Nephrotic syndrome Immunosuppressive Agents Stem Cell Transplantation medicine.drug |
| Zdroj: | International Journal of Hematology. 83:454-458 |
| ISSN: | 0925-5710 |
| DOI: | 10.1532/ijh97.05183 |
| Popis: | Most cases of nephrotic syndrome following stem cell transplantation (SCT) occur 6 months after SCT. The patients are treated with immunosuppressive therapies; however, in some cases treatment is not effective. We used enalapril, an angiotensin-converting enzyme inhibitor (ACEI) and candesartan, an angiotensin II receptor blocker (ARB), for the control of proteinuria in a case of immunosuppressive treatment (IST)-resistant nephrotic syndrome. A 15-year-old boy with acute lymphoblastic leukemia underwent allogeneic peripheral blood SCT from a completely HLA-matched sibling after completion of a conditioning regimen composed of 12-Gy doses of total-body irradiation, 600 mg/m2 thiotepa, and 140 mg/m2 melphalan. Twenty-eight months after SCT, minimal-change nephrotic syndrome was diagnosed on the basis of biopsy findings. Although neither cyclosporine (trough level, 100-150 ng/mL) nor corticosteroid was effective, proteinuria disappeared 2 months after the beginning of treatment with tacrolimus (trough level, 13-20 ng/mL), and remission was maintained for 23 months. Nephrotic syndrome recurred, however, and was resistant to tacrolimus. Findings at the second renal biopsy revealed membranous nephropathy. An ARB (candesartan, 4 mg/ day) in combination with an ACEI (enalapril, 5 mg/day) was started. Proteinuria improved within 2 weeks. We suggest that ARB combined with ACEI can be used to control proteinuria in patients with IST-resistant nephrotic syndrome after SCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink